Alzheon, a Farmingham, MA-based clinical-stage biopharmaceutical company, raised $100M in Series E funding.
The round was led by Alerce Medical Technology Partners.
The company, which previously raised $50M through a Series D financing round in 2022, intends to use the funds to expand operations and its R&D Sector.
Led by Martin Tolar, MD, PhD, Founder, President, and CEO, Alzheon is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders. It is committed to developing innovative medicines by directly addressing the underlying pathology of neurodegeneration. Its lead Alzheimer’s clinical candidate, ALZ-801/valiltramiprosate, is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD. ALZ-801 is an oral small molecule that has been observed to fully block the formation of neurotoxic soluble amyloid oligomers in preclinical tests. Its clinical expertise and technology platform are focused on developing drug candidates and diagnostic assays using a precision medicine approach based on individual genetic and biomarker information to advance therapies with an impact for patients.
FinSMEs
14/06/2024